ISRCTN ISRCTN31514446
DOI https://doi.org/10.1186/ISRCTN31514446
ClinicalTrials.gov number NCT00002582
Secondary identifying numbers G9437812
Submission date
06/04/2000
Registration date
06/04/2000
Last edited
07/05/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Study website

Contact information

Ms Judith Bliss
Scientific

Section of Epidemiology
The Institute of Cancer Research
15 Cotswold Road
Sutton
SM2 5NG
United Kingdom

Phone +44 (0)20 8722 4040
Email abc-icrctsu@icr.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific title
Study acronymABC
Study hypothesisTo determine the value of adding cytotoxic chemotherapy and/or (in premenopausal women) ovarian suppression to prolonged tamoxifen in women with early breast cancer.
Ethics approval(s)Not provided at time of registration
ConditionBreast cancer
InterventionCytotoxic chemotherapy and/or (in premenopausal women) ovarian suppression and prolonged tamoxifen/tamoxifen
Intervention typeOther
Primary outcome measureThe main endpoint used for evaluation of treatment efficacy will be overall survival based on all cause mortality. Relapse-free survival, breast cancer mortality and cardiovascular mortality will also be compared. In a subset of patients there will be a detailed assessment of quality of life. Health economic consequences will also be determined. Ongoing biological predictors of therapeutic response studies, funded by CRUK and BCC.
Secondary outcome measuresNot provided at time of registration
Overall study start date01/01/1993
Overall study end date30/09/2005

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target number of participants6000
Participant inclusion criteriaAll women with early invasive breast cancer requiring adjuvant systemic therapy are eligible for the trial providing they have:
1. Early (operable) breast cancer
2. Histological confirmation of invasive carcinoma
3. No previous malignancy (except carcinoma in situ [CIS] cervix or basal cell carcinoma)
4. Received no previous systemic treatment for their disease
5. Given consent and available for subsequent follow-up
Participant exclusion criteriaNot provided at time of registration
Recruitment start date01/01/1993
Recruitment end date30/09/2005

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Section of Epidemiology
Sutton
SM2 5NG
United Kingdom

Sponsor information

Institute of Cancer Research (UK)
Research organisation

123 Old Brompton Road
London
SW7 3RP
United Kingdom

Phone +44 (0)20 7352 8133
Email abc-icrctsu@icr.ac.uk
Website http://www.icr.ac.uk/
ROR logo "ROR" https://ror.org/043jzw605

Funders

Funder type

Research council

Medical Research Council (UK)
Government organisation / National government
Alternative name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 04/04/2007 Yes No
Results article results 14/03/2012 Yes No